New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing

New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing

“How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” authored by Alex Brill and Christy Robinson, explains how reference biologic manufacturers create thickets of overlapping, weaker follow-on patents to keep competitors from entering the market. The paper highlights how originators have strong incentives to protect their profit streams and have found patent thickets to be an easy way to significantly extend the duration of monopolies in the US, preventing access to more affordable medicines for patients.

Tackle the Tax Gap

Tackle the Tax Gap

The Senate Finance Committee held an important subcommittee hearing this week, “Closing the Tax Gap: Lost Revenue from Noncompliance and the Role of Offshore Tax Evasion.” The “tax gap,” which is the difference between the amount of tax rightfully owed by US taxpayers and the amount of tax actually paid, is not small.

Corporate Tax Hike Vs. Carbon Tax: Economic Trade-Offs

Corporate Tax Hike Vs. Carbon Tax: Economic Trade-Offs

President Biden has announced two ambitious, entwined economic policy agendas: raising the corporate tax rate and other taxes on large businesses to pay for a significant increase in spending on a broadly defined set of infrastructure objectives. While the case for at least some increase in infrastructure spending is sound, the case for unwinding the corporate tax reforms enacted in 2017 is not.